OncoSec Announces Pricing of $3.5 Million Public Offering
November 30, 2022
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
June 30, 2021
Related Post
-
-
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase
November 30, 2022
-
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
November 29, 2022
-
IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
November 28, 2022